Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$13.96
-2.0%		$17.10
$8.72
▼
$27.41
$518.07M1.24297,216 shs82,684 shs
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
$6.11
-3.2%		$6.98
$1.70
▼
$8.33
$614.71M1.09929,887 shs321,397 shs
Theratechnologies Inc. stock logo
THTX
Theratechnologies
$3.42
+0.9%		$3.35
$2.24
▼
$3.40
$157.21M0.51506,857 shs3.27 million shs
Valneva SE Sponsored ADR stock logo
VALN
Valneva
$6.19
-0.6%		$6.07
$4.75
▼
$12.23
$586.90M1.6764,183 shs9,306 shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
+0.35%-15.09%-16.24%-22.96%+9.71%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-0.79%+7.86%-21.71%-2.02%+168.51%
Theratechnologies Inc. stock logo
THTX
Theratechnologies
0.00%0.00%0.00%0.00%+0.86%
Valneva SE Sponsored ADR stock logo
VALN
Valneva
-2.05%-5.33%-8.26%+19.85%-39.61%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$13.96
-2.0%		$17.10
$8.72
▼
$27.41
$518.07M1.24297,216 shs82,684 shs
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
$6.11
-3.2%		$6.98
$1.70
▼
$8.33
$614.71M1.09929,887 shs321,397 shs
Theratechnologies Inc. stock logo
THTX
Theratechnologies
$3.42
+0.9%		$3.35
$2.24
▼
$3.40
$157.21M0.51506,857 shs3.27 million shs
Valneva SE Sponsored ADR stock logo
VALN
Valneva
$6.19
-0.6%		$6.07
$4.75
▼
$12.23
$586.90M1.6764,183 shs9,306 shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
+0.35%-15.09%-16.24%-22.96%+9.71%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-0.79%+7.86%-21.71%-2.02%+168.51%
Theratechnologies Inc. stock logo
THTX
Theratechnologies
0.00%0.00%0.00%0.00%+0.86%
Valneva SE Sponsored ADR stock logo
VALN
Valneva
-2.05%-5.33%-8.26%+19.85%-39.61%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
2.83
Moderate Buy$29.60112.03% Upside
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
3.00
Buy$12.78109.30% Upside
Theratechnologies Inc. stock logo
THTX
Theratechnologies
1.00
SellN/AN/A
Valneva SE Sponsored ADR stock logo
VALN
Valneva
1.67
Reduce$9.3050.36% Upside

Current Analyst Ratings Breakdown

Latest THTX, VALN, STTK, and CBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/14/2026
Valneva SE Sponsored ADR stock logo
VALN
Valneva
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/14/2026
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$27.00
9/11/2026
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/27/2026
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$27.00
8/24/2026
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageStrong-Buy$18.00
8/24/2026
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/24/2026
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageStrong-Buy$18.00
8/24/2026
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/11/2026
Valneva SE Sponsored ADR stock logo
VALN
Valneva
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$12.00
8/11/2026
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$18.00 ➝ $14.00
8/11/2026
Valneva SE Sponsored ADR stock logo
VALN
Valneva
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$12.00
(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$10.84M47.83N/AN/A$14.32 per share0.97
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
$1M612.70N/AN/A$1.30 per share4.70
Theratechnologies Inc. stock logo
THTX
Theratechnologies
$84.38M1.86N/AN/A($0.55) per share-6.22
Valneva SE Sponsored ADR stock logo
VALN
Valneva
$197.56M2.97N/AN/A$1.39 per share4.45
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-$153.94M-$6.72N/AN/AN/AN/A-101.50%-86.86%11/5/2026 (Estimated)
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-$48.81M-$0.51N/AN/AN/AN/A-43.57%-40.90%11/10/2026 (Estimated)
Theratechnologies Inc. stock logo
THTX
Theratechnologies
-$8.31M-$0.19N/A48.84N/A-10.85%N/A-9.83%N/A
Valneva SE Sponsored ADR stock logo
VALN
Valneva
-$130.33M-$2.11N/A14.06N/A-110.33%-153.20%-39.50%11/19/2026 (Estimated)

Latest THTX, VALN, STTK, and CBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Valneva SE Sponsored ADR stock logo
VALN
Valneva
-$0.1886-$0.40-$0.2114-$0.38$44.17 million$39.37 million
8/11/2026Q2 2026
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-$0.1241-$0.12+$0.0041-$0.12N/AN/A
7/30/2026Q2 2026
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-$0.7357-$0.74-$0.0043-$0.74$0.36 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/AN/AN/AN/AN/A
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
N/AN/AN/AN/AN/A
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/AN/AN/AN/AN/A
Valneva SE Sponsored ADR stock logo
VALN
Valneva
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/A
9.66
9.66
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
N/A
27.59
27.59
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/A
0.84
0.65
Valneva SE Sponsored ADR stock logo
VALN
Valneva
2.04
2.16
1.69

Institutional Ownership

CompanyInstitutional Ownership
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
75.19%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
58.74%
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/A
Valneva SE Sponsored ADR stock logo
VALN
Valneva
11.39%

Insider Ownership

CompanyInsider Ownership
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
24.84%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
8.79%
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/A
Valneva SE Sponsored ADR stock logo
VALN
Valneva
14.91%
CompanyEmployeesShares OutstandingFree FloatOptionable
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
4437.14 million27.92 millionNo Data
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
40100.36 million91.54 millionOptionable
Theratechnologies Inc. stock logo
THTX
Theratechnologies
14045.98 millionN/AOptionable
Valneva SE Sponsored ADR stock logo
VALN
Valneva
67494.89 million80.74 millionNot Optionable

Recent News About These Companies

Analyzing Valneva (NASDAQ:VALN) and Septerna (NASDAQ:SEPN)
September 24 at 4:00 AM  |  defenseworld.netD
Football fundraiser collects £2k for Livingston charity Team Jak Foundation
September 22 at 2:37 PM  |  msn.comhttps://www.msn.com/en-gb/sport/american_football/football-fundraiser-collects-2k-for-livingston-charity-team-jak-foundation/ar-AA2cJAPq
Valneva's Lyme Shot Nears EU Verdict as Pipeline Readouts and Cost Cuts Converge
September 21, 2026  |  ad-hoc-news.deA
Pfizer (PFE), Valneva (VALN) Lyme Vaccine Moves to EMA Review Despite Phase 3 Caveat
September 15, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/pfizer-pfe-valneva-valn-lyme-vaccine-moves-to-ema-review-despite-phase-3-caveat-1821126/
Valneva Aktie: Umsatz bricht um 33 Prozent ein
September 9, 2026  |  boerse-express.comB
Valneva Aktie: Verkauf von Nantes vereinbart
September 6, 2026  |  boerse-express.comB
Valneva (NASDAQ:VALN) Trading Up 7.1% - Time to Buy?
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-valneva-nasdaq-valn-trading-up-71-time-to-buy-2026-09-02/
Valneva (NASDAQ:VALN) Shares Gap Up - Time to Buy?
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-valneva-nasdaq-valn-shares-gap-up-time-to-buy-2026-09-01/
Potential Moderna-style share surge? Takeover candidates Evotec, Valneva and Vidac Pharma in focus — analysts bullish
September 1, 2026  |  msn.comhttps://www.msn.com/en-ca/news/other/potential-moderna-style-share-surge-takeover-candidates-evotec-valneva-and-vidac-pharma-in-focus-analysts-bullish/ar-AA2bjBV0
Valneva's Property Sale Buys Breathing Room as Travel-Vaccine Demand Sours
August 30, 2026  |  ad-hoc-news.deA
Valneva's High-Wire Act: Can Cost Cuts and a Pivotal EMA Review Bridge the Gap to 2026?
August 29, 2026  |  ad-hoc-news.deA
Answers to 3 questions about a potential Lyme vaccine
August 28, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/answers-to-3-questions-about-a-potential-lyme-vaccine/ar-AA2b7FAB
Valneva's Regulatory Tailwind Collides With a Deepening Loss Profile
August 24, 2026  |  ad-hoc-news.deA
Valneva's Analyst Divide Widens as EMA Review Puts Statistical Questions in the Spotlight
August 20, 2026  |  ad-hoc-news.deA
Valneva (VALN) Q2 2026 Earnings Call Transcript
August 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/valneva-valn-q2-2026-earnings-194457376.html
EMA validates marketing authorisation application of Pfizer & Valneva’s PF-07307405, a 6-valent OspA-based Lyme disease vaccine
August 17, 2026  |  pharmabiz.comP
EMA validates Pfizer and Valneva’s Lyme disease vaccine
August 17, 2026  |  msn.comhttps://www.msn.com/en-us/health/medical/ema-validates-pfizer-and-valneva-s-lyme-disease-vaccine/ar-AA2ajQPm
Pfizer, Valneva Lyme vaccine starts review in Europe
August 15, 2026  |  pharmaphorum.comP
Valneva Shares Climb After Lyme Disease Vaccine Receives EMA Application Acceptance
August 15, 2026  |  marketwatch.comhttps://www.marketwatch.com/story/valneva-shares-climb-after-lyme-disease-vaccine-receives-ema-application-acceptance-8a143cc5
Update: Valneva Shares Gain as Lyme Vaccine Candidate Gets EMA Review
August 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/valneva-shares-gain-lyme-vaccine-112557623.html
A Lyme disease vaccine may finally be on the way. Why did it take so long?
August 14, 2026  |  nationalpost.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

Crescent Biopharma stock logo

Crescent Biopharma NASDAQ:CBIO

$13.96 -0.28 (-1.97%)
As of 02:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Shattuck Labs stock logo

Shattuck Labs NASDAQ:STTK

$6.10 -0.21 (-3.25%)
As of 02:24 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

Theratechnologies stock logo

Theratechnologies NASDAQ:THTX

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Valneva stock logo

Valneva NASDAQ:VALN

$6.18 -0.04 (-0.56%)
As of 02:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas